TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Condition: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Interventions: Drug: TAK-788; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin Sponsor: Millennium Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research